Aflibercept Biosimilar MYL-1701P vs Reference Aflibercept in DME
Susan B. Bressler,Abhijit Barve,Prasanna C. Ganapathi,Katrin Beckmann,Rajendra S. Apte,Dennis M. Marcus,Kristine Baumane,Somesh Agarwal,Piotr Oleksy,David A. Reichstein,Sunil S. Patel,Jan Ernest,Rozsa Dégi,Vishali Gupta,Genichiro Kishino,Motohiro Kamei,Subramanian Loganathan,INSIGHT Study Group,Nauman A Chaudhry,David A Reichstein,Ali R Tabassian,Howard F Fine,Raymond N Sjaarda,Dennis M Marcus,Mark R Barakat,Pravin U Dugel,,David A Eichenbaum,Amr L Dessouki,Adam S Berger,Bryan N Angle,Margaret A Chang,Sunil S Patel,David M Brown,Allen B Thach,Carl W Baker,Alan J Gordon,Sam E Mansour,Gregory M Fox,Daniel Virgil Alfaro,John B Davies,Ghassan R Ghorayeb,Glenn L Stoller,Thomas Mark Johnson,Jan Nemcansky,Jiri Rehak,Jan Studnicka,Jan Ernest,Vladimir Korda,Miroslav Veith,Daniel Krzyzanek,Bohdana Kalvodova,Pavel Stodulka,Nicolas Feltgen,Katrin Lorenz PD,Salvatore Grisanti,Maria- Andreea Gamulescu,Ulrich Kellner,Walter Sekundo,Claudia Dahlke,Oliver Zeitz,Kristine Baumane,Guna Laganovska,Signe Ozolina,Attila Vajas,Andras Seres,Alexis Tsorbatzoglou,Judit Radnoti,Katalin K Kiss,Katalin Gombos,Rozsa Degi,Balazs Varsanyi,Agnes Kerenyi,Sumiyo Noge,Tomoyuki Muramatsu,Tatsushi Kaga,Hideyasu Oh,Miki Watanabe,Yuji Oshima,Hideaki Fujita,Genichiro Kishino,Tsukasa Hanemoto,Koji Murata,Takashi Kitaoka,Isao Saito,Teruyo Tanabe,Nobuyuki Ebihara,Hiroko Imaizumi,Kiyoshi Ishii,Motohiro Kamei,Minoru Furuta,Akira Ojima,Osamu Sawada,Tsutomu Kawasaki,Hiroshi Otake,Norihito Doi,Keitetsu Abe,,Satoshi Matsuda,Namie Kobayashi,Yuki Yoshizumi,Maria Budzinskaya,Oleg Lebedev,Alena Eremina,Andrey Zolotarev,Alekxandr Izmaylov,Alexandr Samoylov,Sergei Astakhov,Yury Astakhov,Dmitry Shkvorchenko,Raja Narayanan,Komal Agarwal,Shroff Rahul,Sribhargava Natesh,Vishali Gupta,Bhavik Panchal,Hrishikesh Kaza,Minija C K,Virendra Agrawal,Arti Elhence,Umesh Chandra Behera,Lional Raj,Shahana Mazumdar,Naresh Babu Kannan,Naresh Kumar Yadav,Rajpal Vohra,Somesh Aggarwal,Ashwini Sonawane,Veerappan R Saravanan,Rohan R Chauhan,Ewa Maria Fluder,Jerzy Nawrocki,Edward Wylegala,Dominik Zalewski,Piotr Oleksy,Emilia Borcz
DOI: https://doi.org/10.1001/jamaophthalmol.2024.3458
IF: 8.253
2024-10-18
JAMA Ophthalmology
Abstract:Importance Biosimilars may be lower-cost alternatives to originator biologic products, potentially offering expanded access or reduced economic burden, but have not been evaluated with aflibercept in diabetic macular edema (DME). Objective To compare efficacy and safety of MYL-1701P, an aflibercept biosimilar, with reference aflibercept (Eylea [Regeneron]) in DME. Design, Setting, and Participants This was a double-masked, randomized clinical trial that included participants at 77 centers across the US, Europe, Japan, and India. Included in the analysis were individuals 18 years and older with type 1 or type 2 diabetes with central DME and best-corrected visual acuity (BCVA) letter score of 73 to 38 in the study eye using an Early Treatment Diabetic Retinopathy Study (ETDRS) chart. Study data were analyzed from October to December 2021. Interventions Formulations of MYL-1701P (0.5-mg vial) or reference aflibercept every 4 weeks for 5 consecutive intravitreal injections, followed by every 8 weeks through week 52. Main Outcomes and Measures The primary outcome was the adjusted difference in least squares mean (SE) change from baseline BCVA letter score at week 8 with an equivalence margin of −3 to +3 letters. Secondary outcomes included change in central subfield thickness (CST), BCVA, number of injections over 52 weeks, incidence of adverse events (AEs), and antidrug antibodies (ADAs). Results A total of 355 participants (mean [SD] age, 62.2 [9.2] years; 216 male [60.8%]) were randomized to MYL-1701P (179 participants [50.4%]) and aflibercept (176 participants [49.6%]). At week 8, mean (SE) change in BCVA was 6.60 (0.55) letters vs 6.56 (0.55) letters in the MYL-1701P vs aflibercept groups. The adjusted mean difference of 0.04 letters (90% CI, −1.16 to 1.24 letters) met the primary outcome. At week 8, mean (SE) change in CST was −112 (7) μm vs −124 (7) μm in the MYL-1701P vs aflibercept groups (adjusted mean difference, 12 μm; 90% CI, −3 to 26 μm). The incidence of treatment-emergent AEs in the MYL-1701P and aflibercept arms were ocular (30.9% [55 of 178] vs 29.5% [52 of 176]), serious ocular (0.6% [1 of 178] vs 1.1% [2 of 176]), nonocular (65.2% [116 of 178] vs 65.3% [115 of 176]), and serious nonocular (16.9% [30 of 178] vs 11.9% [21 of 176]). The mean (SD) total number of injections was 8.4 (2.1) vs 8.7 (1.8) in the MYL-1701P vs aflibercept groups. The incidence of treatment-induced or treatment-boosted ADAs was 2.8% (5 of 177) vs 5.7% (10 of 176) in the MYL-1701P vs aflibercept arms. Conclusions and Relevance MYL-1701P demonstrated clinical equivalence in regard to efficacy, with comparable safety and immunogenicity, to reference aflibercept. These findings support use of MLY-1701P as an alternative to reference aflibercept. Trial Registration ClinicalTrials.gov Identifier:NCT03610646
ophthalmology